Has Angie Song, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,254 in general payments to Angie Song, MD across 50 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Angie Song, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Angie Song, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Angie Song, MD

Otolaryngology/Facial Plastic Surgery · Lompoc, CANPI 1982605259

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Stryker at 43.5% of the total.

$2,254in general payments, 2019–2025

Across 50 payments — averaging $45.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Stryker$981
Spinesmith Holdings, LLC$240
GSK$130
Pacira Pharmaceuticals Incorporated$121
Covidien LP$116
Inspire Medical Systems, Inc.$111
plus $554 from 17 others

What the payments were for

Travel & lodging$1989%
Food & beverage$2,05691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Stryker	9	$981
Spinesmith Holdings, LLC	2	$240
GSK	6	$130
Pacira Pharmaceuticals Incorporated	1	$121
Covidien LP	1	$116
Inspire Medical Systems, Inc.	4	$111
Amgen	3	$71
Mentor Worldwide LLC	3	$56
Exact Sciences	3	$55
Sanofi	2	$45
AstraZeneca(2 entities)	2	$38
Baxter Healthcare	1	$36
Regeneron Healthcare Solutions, Inc.	2	$33
Fisher & Paykel Healthcare Inc	1	$33
Boehringer Ingelheim	2	$33
Bioventus LLC	1	$27
Conmed Corporation	1	$24
Lilly USA, LLC	1	$22
Merck	1	$17
Pfizer	1	$16
Galderma Laboratories, L.p.	1	$16
KCI USA, Inc.	1	$15
Tersera Therapeutics LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ENTELLUS - XPRESS ENT DILATION SYSTEM$163
ENTELLUS - CYCLONE SINONASAL SUCTION/IRRIGATION SYSTEM$137
XPRESS ENT DILATION SYSTEM$131
SPY-PHI SYSTEM$127
ENTELLUS - XPRESS OFFICE START-UP KITS$121
EXPAREL$121
AEQUALIS ASCEND FLEX$117
AEQUALIS PERFORM REVERSED$117
BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION$117

How this compares

$2,254 in reported general payments places this provider in the 60th percentile of 102 otolaryngology/facial plastic surgery providers in California.

See all otolaryngology/facial plastic surgery providers in California →

Medicare billing

Part B allowed, 2024

$135,702

Medicare patients

411

Services billed

1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Azelastine Hcl	50	$1,721
Ipratropium Bromide	34	$1,013
Fluticasone Propionate	69	$734
Nystatin	15	$476
Ofloxacin	12	$396
Omeprazole	18	$173
Montelukast Sodium	18	$112
Prednisone	30	$87

Paid to pharmacies, not to this prescriber.

Other otolaryngology/facial plastic surgery in Lompoc

Sarmela SunderLancaster$85K
Vasu DiviStanford$51K
Jen ChowArcadia$26K
Ryan CasserlyMonterey$23K
Ritvik MehtaCarlsbad$13K
Alexis FurzeNewport Beach$12K
Jahangir SharifiLos Angeles$12K
Henry NguyenRancho Cucamonga$11K
Paul NassifBeverly Hills$10K
Babak AzizzadehBeverly Hills$10K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →